Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
This study evaluated a difficult-to-treat Crohn's disease patient population
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated
